From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement
Interview with Gina Hausmann: The Patient Experience and Having the Conversations That Matter—Part 2

Interview with Gina Hausmann: The Patient Experience and Having the Conversations That Matter—Part 2

View all
FROM THE EDITORS

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

 

Katie Newlin, RN, MSN, AGPCNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

 

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Resources

Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People

Abemaciclib AE Monitoring

Exploring the Treatment Gap in High-Risk HR+, HER2- Early Breast Cancer (EBC): Eligible Patients Not Receiving Abemaciclib in the US

Transgender Breast Cancer Screening

Bone Health in Cancer: ESMO Clinical Practice Guidelines

News & Literature Highlights

European Journal of Cancer

70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups

Breast Cancer

Development of a consensus-based risk stratification algorithm for HR+/HER2- early breast cancer to guide adjuvant CDK4/6i therapy: Outcomes from a multidisciplinary workshop in India

Annals of Surgical Oncology

Neoadjuvant dual-targeted HER2 therapy and neoadjuvant chemo-immunotherapy is associated with improved nodal PCR and reduced axillary surgery

Cancer Treatment and Research Communications

Genomic profiling by circulating tumor DNA in patients with hormone receptor-positive/HER2-negative advanced breast cancer: Prevalence of actionable mutations across treatment lines

Therapeutic Advances in Medical Oncology

Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer

Therapeutic Advances in Medical Oncology

Dalpiciclib combined with endocrine therapy for patients with HR+/HER2- metastatic breast cancer: A multicenter real-world study

Journal of Managed Care and Specialty Pharmacy

Economic value of ribociclib in early breast cancer in the United States

Tumori

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer

Frontiers in Oncology

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

Clinical Breast Cancer

Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

Advertisement
Case Studies

Managing Adverse Events for Women Receiving Adjuvant Breast Cancer Treatment

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

Advertisement
Quizzes
Test your knowledge of adverse event management for women receiving adjuvant breast cancer treatment
Test your knowledge on first-line treatment for metastatic ER+ HER2- breast cancer
Test your knowledge on HR-positive, HER2-negative breast cancer